Abbott Laboratories
ABT Healthcare Medical Devices
Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024. In the quarter to June 2026, revenue grew 13.0%, EPS fell 47.5%, free cash flow grew 28.9% and total debt rose 142.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.
Follow ABT
Abbott Laboratories (ABT) Revenue
Abbott Laboratories's revenue for fiscal 2025 was $44.3B, up 5.67% from $42.0B in fiscal 2024. Over the twelve months to 30 June 2026 it was $46.6B. Over the past ten years it has ranged from $20.4B (fiscal 2015) to $44.3B (fiscal 2025) — the current reading is the highest in ten years. Abbott Laboratories ranks 1st of 140 Medical Devices companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $44.3B | 5.67% |
| FY2024 | $42.0B | 4.59% |
| FY2023 | $40.1B | (8.12%) |
| FY2022 | $43.7B | 1.34% |
| FY2021 | $43.1B | 24.47% |
| FY2020 | $34.6B | 8.48% |
| FY2019 | $31.9B | 4.34% |
| FY2018 | $30.6B | 11.64% |
| FY2017 | $27.4B | 31.35% |
| FY2016 | $20.9B | 2.20% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $12.6B | 12.80% |
| Mar 2026 | $11.2B | (2.57%) |
| Dec 2025 | $11.5B | 0.79% |
| Sep 2025 | $11.4B | 2.04% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ABT Abbott Laboratories | $46.6B |
| MDT Medtronic PLC compare | $37.5B |
| SYK Stryker Corporation compare | $25.8B |
| GEHC GE HealthCare Technologies Inc. compare | $21.3B |
| BSX Boston Scientific Corporation compare | $21.0B |
| PHG Koninklijke Philips N.V. compare | $20.6B |
| EW Edwards Lifesciences Corporation compare | $6.5B |
| STE STERIS plc compare | $6.0B |
| DXCM DexCom, Inc. compare | $5.0B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ABT
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement